Drug Database
Back to search

Iceland· IS-EU/1/20/1508/001

Enhertu

A trastuzumab deruxtecan product containing trastuzumabum deruxtecanum inn, registered in Iceland by DAIICHI SANKYO EUROPE GmbH*. The same ATC class is registered in 12 of our 19 countries.

ATC L01FD04

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedEnhertuATCL01FD04REGISTER NO.IS-EU/1/20/1508/001PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about trastuzumabum deruxtecanum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Trastuzumab deruxtecan is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FD04 (trastuzumab deruxtecan), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 8 of them publish a price we can compare per daily dose
Search trastuzumab deruxtecan products by name

Trastuzumab deruxtecan · ATC L01FD04

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of trastuzumab deruxtecan costs, country by country.

Normalised to the WHO defined daily dose (18 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Trastuzumab deruxtecan · price per daily dose (18 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$337.42
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Trastuzumabum deruxtecanum INN
Manufacturer
DAIICHI SANKYO EUROPE GmbH*
Country
Iceland (IS)
ATC code
L01FD04
ATC class
Trastuzumab deruxtecan
Defined daily dose
18 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    153855
    1 stk x1 hgl
    ISK 282175

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

61 interactions on record for trastuzumab deruxtecan.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check trastuzumab deruxtecan against other medicinesHow interaction checks work

Trastuzumab deruxtecan · interactions on record

61 records

  • 28 severe
  • 33 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Trastuzumab deruxtecan in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All trastuzumab deruxtecan products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Enhertu
  • Norway · Enhertu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/387287ac-1767-469d-899b-1bdd8dc2bc30
GET /v1/drugs/387287ac-1767-469d-899b-1bdd8dc2bc30?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stofn fyrir innrennslisþykkni, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "L01FD04",
  "marketed": true,
  "strength": "100 mg",
  "ma_number": "EU/1/20/1508/001",
  "substance": "Trastuzumabum deruxtecanum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "44214"
}
API referenceMCP serverPlans

See everything about trastuzumab deruxtecan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console